Mark J. Anderton

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 602 citations · Full text

Medicine, Oncology, Pharmacology +15

Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors

Mark J. Anderton, Howard R. Mellor, Alex Bell et al. · Toxicologic Pathology · 2011 · 286 citations

Life Sciences, Cardiology, Pharmacology +13

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

Richard A. Ward, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2013 · 261 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Pharmacokinetics and Tissue Disposition of Indole-3-carbinol and Its Acid Condensation Products after Oral Administration to Mice

Mark J. Anderton, Margaret M. Manson, Richard D. Verschoyle et al. · Clinical Cancer Research · 2004 · 219 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +11

A Kainate Receptor Linked to Nitric Oxide Synthesis from Arginine

John Garthwaite, Eric Southam, Mark J. Anderton · Journal of Neurochemistry · 1989 · 200 citations

Life Sciences, Neuroscience, Pharmacology +17